Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice
- PMID: 18789973
- DOI: 10.1016/j.jviromet.2008.08.011
Immunization with plasmid DNA encoding influenza A virus nucleoprotein fused to a tissue plasminogen activator signal sequence elicits strong immune responses and protection against H5N1 challenge in mice
Abstract
DNA vaccination is an effective means of eliciting both humoral and cellular immunity. Most of influenza vaccines targeted at hemagglutinin (HA) show efficient immunogenicity for protecting subjects against influenza virus infection. However, major antigenic variations of HA may facilitate the virus in developing resistance against such vaccines. DNA vaccines encoding conserved antigens protect animals against diverse viral subtypes, but their potency requires further improvement. In the present study, a DNA vaccine encoding the conserved nucleoprotein (NP) with a tissue plasminogen activator (tPA) signal sequence (ptPAs/NP) was generated, and immune responses were examined in vaccinated mice. A higher level of NP expression and secretion was observed in lysates and supernatants of the cells transfected with ptPAs/NP when compared to a plasmid encoding the wild-type full-length NP (pflNP). Immunofluorescence studies showed the cytoplasmic localization of the NP protein expressed from ptPAs/NP, but not from pflNP. In mice, the ptPAs/NP vaccine elicited higher levels of the NP-specific IgG and CD8(+) T cell-stimulating responses than that of pflNP. Vaccination with ptPAs/NP efficiently cleared the homologous H5N1 influenza virus in the infected lungs and induced partial cross-protection against heterologous, highly pathogenic H5N1 strains in mice. Our results may contribute to the development of protective immunity against diverse, highly pathogenic H5N1 virus subtypes.
Similar articles
-
Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice.Antiviral Res. 2009 Mar;81(3):253-60. doi: 10.1016/j.antiviral.2008.12.009. Epub 2009 Jan 9. Antiviral Res. 2009. PMID: 19135483
-
Mutant influenza A virus nucleoprotein is preferentially localized in the cytoplasm and its immunization in mice shows higher immunogenicity and cross-reactivity.Vaccine. 2007 May 22;25(21):4291-300. doi: 10.1016/j.vaccine.2007.02.074. Epub 2007 Mar 12. Vaccine. 2007. PMID: 17403560
-
The virus-induced signaling adaptor molecule enhances DNA-raised immune protection against H5N1 influenza virus infection in mice.Vaccine. 2011 Mar 21;29(14):2561-7. doi: 10.1016/j.vaccine.2011.01.060. Epub 2011 Feb 16. Vaccine. 2011. PMID: 21303708
-
Identification of effective constituents of influenza vaccine by immunization with plasmid DNAs encoding viral proteins.Jpn J Infect Dis. 2000 Dec;53(6):219-28. Jpn J Infect Dis. 2000. PMID: 11227019 Review.
-
Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines.Jpn J Infect Dis. 2005 Aug;58(4):195-207. Jpn J Infect Dis. 2005. PMID: 16116250 Review.
Cited by
-
OVX836 a recombinant nucleoprotein vaccine inducing cellular responses and protective efficacy against multiple influenza A subtypes.NPJ Vaccines. 2019 Jan 23;4:4. doi: 10.1038/s41541-019-0098-4. eCollection 2019. NPJ Vaccines. 2019. PMID: 30701093 Free PMC article.
-
Screening of viral-vectored P. falciparum pre-erythrocytic candidate vaccine antigens using chimeric rodent parasites.PLoS One. 2021 Jul 12;16(7):e0254498. doi: 10.1371/journal.pone.0254498. eCollection 2021. PLoS One. 2021. PMID: 34252120 Free PMC article.
-
Rabies DNA vaccine: no impact of MHC class I and class II targeting sequences on immune response and protection against lethal challenge.Vaccine. 2009 Mar 26;27(15):2128-37. doi: 10.1016/j.vaccine.2009.01.128. Epub 2009 Feb 6. Vaccine. 2009. PMID: 19356616 Free PMC article.
-
A novel vaccine against Crimean-Congo Haemorrhagic Fever protects 100% of animals against lethal challenge in a mouse model.PLoS One. 2014 Mar 12;9(3):e91516. doi: 10.1371/journal.pone.0091516. eCollection 2014. PLoS One. 2014. PMID: 24621656 Free PMC article.
-
Expression of the SARS-CoV-2 receptor-binding domain by live attenuated influenza vaccine virus as a strategy for designing a bivalent vaccine against COVID-19 and influenza.Virol J. 2024 Apr 9;21(1):82. doi: 10.1186/s12985-024-02350-w. Virol J. 2024. PMID: 38589848 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous